Jens Juul Holst
Department of Biomedical Sciences
The Panum Institute
University of Copenhagen
2200, Copenhagen
Denmark
Name/email consistency: high
- Glucagon and glucagon-like peptides 1 and 2. Holst, J.J. Results. Probl. Cell. Differ (2010)
- The incretin system and its role in type 2 diabetes mellitus. Holst, J.J., Vilsbøll, T., Deacon, C.F. Mol. Cell. Endocrinol. (2009)
- Glucagon-like peptide-1, glucose homeostasis and diabetes. Holst, J.J., Deacon, C.F., Vilsbøll, T., Krarup, T., Madsbad, S. Trends. Mol. Med (2008)
- Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. Holst, J.J., Hartmann, B., Gottschalck, I.B., Jeppesen, P.B., Miholic, J., Henriksen, D.B. Scand. J. Gastroenterol. (2007)
- The physiology of glucagon-like peptide 1. Holst, J.J. Physiol. Rev. (2007)
- Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Holst, J.J. Diabetologia (2006)
- Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Holst, J.J., Deacon, C.F. Diabetologia (2005)
- Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Holst, J.J. Expert. Opin. Emerg. Drugs (2004)
- Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Holst, J.J., Gromada, J. Am. J. Physiol. Endocrinol. Metab. (2004)
- Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Holst, J.J., Deacon, C.F. Curr. Opin. Pharmacol (2004)
- The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Holst, J.J., Orskov, C. Diabetes (2004)
- On the physiology of GIP and GLP-1. Holst, J.J. Horm. Metab. Res. (2004)
- Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Holst, J.J. Adv. Exp. Med. Biol. (2003)
- Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?. Holst, J.J. BioDrugs (2002)
- The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno--ileal loop?. Hansen, L., Holst, J.J. Regul. Pept. (2002)
- Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Holst, J.J. Diabetes Metab. Res. Rev. (2002)
- Incretin hormones--an update. Holst, J.J., Orskov, C. Scand. J. Clin. Lab. Invest. Suppl. (2001)
- Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2. Holst, J.J. Regul. Pept. (2000)
- Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1. Holst, J.J. Expert. Opin. Investig. Drugs (1999)
- Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Holst, J.J., Deacon, C.F. Diabetes (1998)
- On the treatment of diabetes mellitus with glucagon-like peptide-1. Holst, J.J., Deacon, C., Toft-Nielsen, M.B., Bjerre-Knudsen, L. Ann. N. Y. Acad. Sci. (1998)
- On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects. Holst, J.J., Toft-Nielsen, M.B., Orskov, C., Nauck, M., Willms, B. Ann. N. Y. Acad. Sci. (1996)